Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.82 |
| ▸ | BLM | P54132 | 4/20 | 0.80 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine Oxide SCHEMBL162929 | 1.00 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL29369999 | 1.00 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL667605 | 0.99 | CYP2C19 (0.98) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL1490299 | 0.98 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL1490302 | 0.98 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL824874 | 0.90 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL34463463 | 0.90 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL1321572 | 0.89 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL30647266 | 0.89 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL29389879 | 0.89 | PABPC1 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 894 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIV UTAH RES FOUND (US) | 2024-10-10 | — | — | US | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| US-20240191267-A1 | Tropane Alkaloid Transporters and Methods of Making Tropane Alkaloids Using the Same | HERCULES CAPITAL, INC., AS AGENT | 2024-06-13 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4314301-A1 | TROPANE ALKALOID TRANSPORTERS AND METHODS OF MAKING TROPANE ALKALOIDS USING THE SAME | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117500928-A | Tropane alkaloid transporter and method for producing tropane alkaloid using same | 小利兰·斯坦福大学托管委员会 | 2024-02-02 | — | — | CN | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| WO-2022266407-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-6784194-B2 | FOR INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-08-31 | — | — | US | claimed |
| EP-0956019-B1 | NOVEL THERAPEUTIC APPLICATION OF A THIENYCYCLOHEXYLAMINE DERIVATIVE | SOD CONSEILS RECH APPLIC (FR) | 2003-10-15 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| US-20010056091-A1 | Therapeutic use of a thienylcyclohexylamine derivative | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2001-12-27 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6207685-B1 | INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS BY ADMINISTERING 2-METHYL-1-(1-PIPERIDINYL)-1-(2-THIENYL)-CYCLOHEXANE IN PURE RACEMIC, DIASTEREOISOMERIC OR ENANTIOMERIC FORM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-03-27 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | ACHE, MUC1, NEU3 | CYP2C19 2010/4885CHRM2 24/4885BLM 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.